Burning Rock Biotech Ltd (BNR) - Total Assets
Based on the latest financial reports, Burning Rock Biotech Ltd (BNR) holds total assets worth $820.90 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does Burning Rock Biotech Ltd reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Burning Rock Biotech Ltd - Total Assets Trend (2017–2025)
This chart illustrates how Burning Rock Biotech Ltd's total assets have evolved over time, based on quarterly financial data. Explore BNR long-term investment intensity to see how much of total assets are deployed in long-term investments.
Burning Rock Biotech Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Burning Rock Biotech Ltd's total assets of $820.90 Million consist of 90.0% current assets and 10.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 58.6% |
| Accounts Receivable | $182.03 Million | 22.2% |
| Inventory | $57.01 Million | 6.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $284.00K | 0.0% |
| Goodwill | $284.18K | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Burning Rock Biotech Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BNR market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Burning Rock Biotech Ltd's current assets represent 90.0% of total assets in 2025, an increase from 74.7% in 2017.
- Cash Position: Cash and equivalents constituted 58.6% of total assets in 2025, up from 13.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 22.2% of total assets.
Burning Rock Biotech Ltd Competitors by Total Assets
Key competitors of Burning Rock Biotech Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Prodia Widyahusada Tbk PT
JK:PRDA
|
Indonesia | Rp2.57 Trillion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Optipharm.CO.LTD
KQ:153710
|
Korea | ₩40.77 Billion |
|
AroCell AB
ST:AROC
|
Sweden | Skr122.88 Million |
|
Avricore Health Inc
V:AVCR
|
Canada | CA$563.12K |
|
Check-Cap Ltd
F:7CC
|
Germany | €7.49 Million |
|
ALPHAHELIX MOL.DIAGN. SK1
F:4MB
|
Germany | €13.12 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
Burning Rock Biotech Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.99 | 3.02 | 7.32 |
| Quick Ratio | 2.76 | 2.76 | 6.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $491.92 Million | $509.09 Million | $1.91 Billion |
Burning Rock Biotech Ltd - Advanced Valuation Insights
This section examines the relationship between Burning Rock Biotech Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.17 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -7.3% |
| Total Assets | $820.90 Million |
| Market Capitalization | $70.07 Million USD |
Valuation Analysis
Below Book Valuation: The market values Burning Rock Biotech Ltd's assets below their book value (0.09x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Burning Rock Biotech Ltd's assets decreased by 7.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Burning Rock Biotech Ltd (2017–2025)
The table below shows the annual total assets of Burning Rock Biotech Ltd from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $820.90 Million | -7.28% |
| 2024-12-31 | $885.30 Million | -14.87% |
| 2023-12-31 | $1.04 Billion | -34.49% |
| 2022-12-31 | $1.59 Billion | -30.33% |
| 2021-12-31 | $2.28 Billion | -14.44% |
| 2020-12-31 | $2.66 Billion | +214.20% |
| 2019-12-31 | $847.56 Million | +127.43% |
| 2018-12-31 | $372.67 Million | -6.91% |
| 2017-12-31 | $400.33 Million | -- |
About Burning Rock Biotech Ltd
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction test… Read more